Home > Insider Trading > Filing (0000947871-21-000334)

Filing Details

Accession Number:: 0000947871-21-000334
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-15 20:55:51
Reporting Period:: 2021-03-11

Accepted Time:: 2021-03-15 20:55:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1796280	Oric Pharmaceuticals Inc.	ORIC	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue 54Th Floor New York NY 10022		Yes	No	No	No
1682115	Orbimed Capital Gp Vi Llc	601 Lexington Avenue, 54Th Floor New York NY 10022		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-03-11	58,551	$33.04	2,707,166	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-03-12	90,521	$30.29	2,616,645	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2021-03-15	89,210	$29.14	2,527,435	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

These shares of the Issuer's common stock were sold in a block order at a price of $33.04 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VI, LP ("OPI VI").
These shares of the Issuer's common stock are held of record by OPI VI. OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
This report is being jointly filed by OrbiMed Advisors and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon ("Gordon") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
These shares of the Issuer's common stock were sold in a block order at a price of $30.29 pursuant to a Rule 10b5-1 trading plan established by OPI VI.
These shares of the Issuer's common stock were sold in a block order at a price of $29.14 pursuant to a Rule 10b5-1 trading plan established by OPI VI.